



**HAL**  
open science

## **Efficacy of instillation treatment with hyaluronic acid in relieving symptoms in patients with BPS/IC and uncomplicated recurrent urinary tract infections - Long-term results of a multicenter study**

Ioan Scarneciu, Simona Bungau, Aura-Mihaela Lupu, Camelia C. Scarneciu, Ovidiu Gabriel Bratu, Orsolya Martha, Delia Mirela Tit, Lotfi Aleya, Sorin Lupu

### ► To cite this version:

Ioan Scarneciu, Simona Bungau, Aura-Mihaela Lupu, Camelia C. Scarneciu, Ovidiu Gabriel Bratu, et al.. Efficacy of instillation treatment with hyaluronic acid in relieving symptoms in patients with BPS/IC and uncomplicated recurrent urinary tract infections - Long-term results of a multicenter study. *European Journal of Pharmaceutical Sciences*, 2019, 139, pp.105067. 10.1016/j.ejps.2019.105067 . hal-02286095

**HAL Id: hal-02286095**

**<https://hal.science/hal-02286095>**

Submitted on 20 Jul 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License



**28 Abstract**

29 The purpose of this study is to evaluate the efficacy of intra-vesical instillations with hyaluronic  
30 acid (HA) in relieving lower urinary tract irritation symptoms in patients with urinary tract  
31 infections (UTIs) and bladder pain syndrome/interstitial cystitis (BPS/IC). This research,  
32 conducted in Romania, includes 30 patients with UTIs (Group I) and 24 with BPS/IC (Group II)  
33 as defined by European Association of Urology (EAU) Diagnostic Criteria. Data were collected  
34 prospectively, using pre- and post-treatment questionnaires for pelvic pain with a symptom scale  
35 for urination and frequency as well as visual analog scale (VAS) pain quizzes. At follow-up visits,  
36 at an average of 20 months, a significant improvement in urinary bladder pain, day-time urinary  
37 frequency and quality of life was observed in Group I patients. Group II patients experienced  
38 significant improvement in urinary bladder pain, urgency, nocturia and quality of life at the 15-  
39 month follow-up visit. Eighteen patients (75%) showed a complete response to intravesical HA  
40 instillations and required no further treatment. Our study demonstrates that intravesical HA  
41 instillations may be considered as an important treatment component, with long term positive  
42 effects in therapeutic strategy for optimal results in uncomplicated recurrent UTIs and BPS/IC,  
43 with good compliance and minimal side effects.

44

45 **Keywords:** hyaluronic acid; bladder pain; interstitial cystitis; urinary infection

46

47

48

49

50

## 51 **1. Introduction**

52 Uncomplicated recurrent UTIs are conditions just as incapacitating, expensive and frustrating, for  
53 patients and medical staff alike. Almost 50% of all women will have UTIs during their lifetime  
54 and for 33% this happens before the age of 24. Up to 35% of UTIs will repeat within 3-6 months  
55 (Foxman, 2000; 2002). An uncomplicated UTI is defined as an infection that occurs in a healthy  
56 person in the absence of structural or functional abnormalities of the urinary tract. Recurrent  
57 uncomplicated UTI may be defined as 3 or more uncomplicated UTIs within 12 months (Hooton,  
58 2001; Zhong et al., 2011). Also, the elevated incidence of this disease is associated with high cost  
59 due to the repetitive use of many antibiotics and other treatments, as well as to multiple visits to  
60 GPs, gynecologists or urologists (Foxman, 2002; Ronald 2002; Raymond et al., 2012).

61 BPS/IC is a heterogeneous chronic disabling condition affecting the patient's quality of life and  
62 provoking a medical condition necessitating diagnosis and treatment. Over time, numerous names,  
63 definitions, and classifications of this condition have been proposed. According to the Society for  
64 Urodynamics and Female Urology this affliction is characterized by an unpleasant sensation of  
65 pain, discomfort and pressure felt in the region of the bladder and is associated with lower urinary  
66 tract symptoms present for at least 6 months prior to diagnosis, while urinary infection or other  
67 possible identifiable causes are excluded (Hanno et al., 2010; Tit et al., 2017). Though there is no  
68 general agreement on the exact pathophysiology of this disease, in many cases a disorder of the  
69 barrier between the urine and the mucous membrane of the bladder appears to be the mechanism  
70 underlying symptom function and manifestations (Hanno et al., 2010; Magnus et al., 2008).

71 The wide margins in prevalence reported by different authors for BPS/IC lead to an accepted range  
72 of 10-530/100000, a broad interval which reflects a reasonable consensus in reporting the  
73 pathology (Fall et al., 2008; Rovner et al., 2000). A deficiency is assumed to be present in the

74 protective layer of glycosaminoglycans (GAG), the lining of the bladder epithelium which is a  
75 common path in development of BPS/IC and recurrent UTIs (Constantinides et al., 2004; Stav et  
76 al., 2011). Glycosaminoglycan is an important component of the protective liner, the deficiency  
77 being documented in a series of studies on painful bladder syndrome (Hurst et al., 1996), mainly  
78 using a positive potassium chloride sensitivity (PST) or the Parson test and the favorable response  
79 obtained to GAG restorer agents (Parsons et al., 1991; Daha et al., 2008).

80 Various techniques (instillations with chondroitin sulphate, heparin, pentosane polysulphate and  
81 HA) for recovering the layer of GAG from the bladder mucosa level have been used with differing  
82 results. Iavazzo et al. (2007) have shown a varied but positive response (30 to 73%) in patients  
83 with BPS/IC when instillation with HA was used (Leppilahti et al., 2002; Iavazzo et al., 2007). In  
84 patients with recurrent UTIs, Constantinides et al. (2004) obtained promising results with HA,  
85 70% of patients being without recurrence at an average follow-up of 12.4 months. Treatment with  
86 HA was first used with favorable results in patients with BPS/IC and the indication was later  
87 extended to other conditions for which instillation was shown to be effective (recurrent UTIs or  
88 radiation-induced cystitis). When trying to restore the protective barrier of the bladder by agents  
89 with GAG substitution role, doctors encounter great difficulty as therapeutic agents are numerous,  
90 with controversial results, and since adequate studies proving efficiency are lacking (Rovner et al.,  
91 2000; Burkman, 2004). An optimal therapeutic regimen should be based on its ability to relieve  
92 symptoms, improve patients' quality of life and diminish costs (Burkman, 2004). Products  
93 available in Europe and currently used for instillations in the treatment of BPS/IC are listed in  
94 **Table 1.**

95 Our research was a prospective, open and non-randomized study conducted in Romania over a  
96 period of 2 years. The long-term efficacy of instillation treatment with sodium hyaluronate (the

97 only product available on the Romanian pharmaceutical market at the beginning of the study) was  
98 evaluated separately in relieving lower urinary tract irritation symptoms in uncomplicated  
99 recurrent UTI and BPS / IC patients; we considered that HA treatment to be potentially beneficial  
100 since the short-term progression (after 4-6 instillations) proved to be positive, fact specified as well  
101 in the product prospectus and documented in numerous investigations. There are few studies  
102 evaluating the efficacy of HA instillation in these types of pathologies and the number of patients  
103 enrolled in existing trials is small / insufficient (9 patients in Leppilahti's et al. study, 40 patients  
104 in Constantinides's et al. study, and in the study according to Iavazzo et al. (which is actually a  
105 review of 9 other studies), the number of patients is still very low (Leppilahti et al., 2002; Iavazzo  
106 et al., 2007; Constantinides et al., 2004). The results remain contradictory due to this small number  
107 of patients in each study, especially when the treatment is prescribed for urinary infections. Also,  
108 the recommendations are still under discussion and the conclusions remain unclear because of the  
109 same causes (few studies, small number of patients).

110

## 111 **2. Material and methods**

### 112 **2.1. Study Design**

113 The study was conducted from January 1<sup>st</sup>, 2016 through March 2018, in 3 university centers,  
114 located in Romania (Clinic of Urology – Emergency Clinical County Hospital of Brasov, Clinic  
115 of Urology – “Dr. Carol Davila” Central Military Emergency University Hospital of Bucharest,  
116 and Clinic of Urology – Emergency Clinical County Hospital of Targu Mures) on 54 women,  
117 divided into two groups: 30 who had uncomplicated recurrent UTIs (Group I) and 24 who had  
118 BPS/IC (Group II) according to EAU Diagnostic Criteria (Engeler et al., 2018).

119 The inclusion criteria of the patients in the study were as follows:

120 *For Group I:* patients over 18 years, with recurrent and symptomatic uncomplicated UTIs (dysuria,  
121 frequency, urgency, haematuria), with positive urine cultures, after more than 6 months of different  
122 types of treatments (prescribed for the specific condition).

123 *For Group II:* patients over 18 years, fulfilling the EAU criteria for BPS/IC (Engeler et al., 2018):  
124 history of cystoscopy/hydrodistension with a diagnosis of IC confirmed by findings of Hunner's  
125 ulcer or glomerulation, symptoms of bladder pain and urinary urgency (for at least 6 months),  
126 urinary frequency (at least 8 times a day), nocturia (at least twice a night), symptoms not  
127 significantly relieved by antimicrobial agents, anticholinergic drugs, or antispasmodics, pain,  
128 pressure or discomfort associated with the urinary bladder (despite current therapy).

129 The exclusion criteria that our study considered, were:

130 *For Group I:* signs of complicated UTI, conditions possibly leading to complicated infections (i.e.  
131 renal diseases, patients with urinary catheter), pregnancy/breastfeeding, current self-medication  
132 with other treatments for UTI, antibiotic use in the last 7 days, contraindications for instillation  
133 treatment with HA, serious diseases, inability to understand the study design, current or past  
134 participation (within the last 6 months) in a clinical trial.

135 *For Group II:* patient currently pregnant or breastfeeding, intravesical therapy or bladder hydro-  
136 distention within the previous 60 days, history of augmentation cystoplasty, cystectomy,  
137 neurectomy, history of ureteral reflux, evidence of renal impairment (creatinine > twice the upper  
138 limit of normal at first visit, hepatic impairment (AST or ALT >3 times the upper limit of normal  
139 at first visit, clinically significant cardiovascular, respiratory or psychiatric diseases, urinary tract  
140 infection within the past 3 months prior to study entry, active genital herpes or vaginitis, uterine,  
141 cervical, vaginal, or urethral cancer within the past 5 years prior to entering the study, history of  
142 cyclophosphamide or chemical cystitis, urinary tuberculosis or radiation cystitis, history of bladder

143 tumors, inability to understand the study design, current or past participation (within 6 months) in  
144 a clinical trial.

145 Patient distribution was according to the diagnosis, risks and benefits of the indicated treatment.

146 In both groups, they were comparable in age and gender. All data were prospectively collected,

147 stored and processed; also, all steps necessary to establishing the correct diagnosis and potential

148 treatment were respected.

149 All the patients (in both groups) received intravesical HA instillations in doses of 50 mL / 40 mg

150 after the bladder was emptied. Subjects were advised to maintain the instilled substance in the

151 bladder for a minimum of 30 minutes, but preferably for 1-2 hours (following the product

152 guidelines). The procedure was initially carried out once a week over a period of 4 weeks and then

153 continued once every month (for  $23.4 \pm 5.92$  weeks for Group I and  $21.9 \pm 8.79$  weeks for Group II).

154 Group I (30 patients) received a low dose of an antibiotic, while Group II did not. Patients were

155 evaluated throughout the treatment period and post-instillation clinical parameters were monitored

156 at 15-20 months following treatment, with placement of therapeutic effects taking place over time.

157

## 158 **2.2. Clinical investigations**

159 All patients received pre- and post-treatment questionnaires ("The Pelvic Pain and

160 Urinary/Frequency Patient Symptom Scale Questionnaires" (PUF)) to assess their symptoms.

161 Urodynamic studies were performed in all patients in both groups in order to exclude any other

162 pathological cause of the symptoms. The PUF questionnaire, developed by C. Lowell Parsons, is

163 a rapid and informative diagnostic tool used to screen patients with chronic pelvic pain; it uses a

164 symptom score (which measures how often a patient experiences problems) and a bother score

165 (which notes the degree to which the symptoms bother the patient); the bother and symptom score



166 combine for a total PUF score. Scores range from 0 to 35; a score greater than 12 is considered  
167 indicative of significant symptoms (Parsons et al., 2002; Brewer et al., 2007). Twelve patients  
168 (40%) in Group I showed evidence of detrusor hyperactivity (OAB) in urodynamic tests, while the  
169 remaining 18 patients had a normal urodynamic evaluation. All patients in Group II presented  
170 urodynamic evaluations confirming the absence of OAB and additional parameters meeting the  
171 criteria for inclusion of EAU diagnostic data.

172 Pain was assessed using a visual analog scale (VAS), and quality of life was also evaluated. In  
173 pain research VAS remains one of the most commonly used measures of pain intensity.  
174 Nevertheless, questions remain concerning interpretation of results (Jensen et al., 1986;  
175 Burckhardt and Jones, 2003). VAS is a continuous scale comprised of a horizontal (HVAS) or  
176 vertical (VVAS) line, usually 100 mm in length, anchored by 2 verbal descriptors, one for each  
177 symptom extreme (Jensen et al., 1986). Though no consensus exists, the following cut points on  
178 the pain VAS are recommended: no pain (0-4 mm), mild pain (5-44 mm), moderate pain (45-74  
179 mm), and severe pain (75-100 mm) (Jensen et al., 2003).

180 For the quality of life evaluation, we used The Quality of Life Scale (QOLS), a questionnaire  
181 created by John Flanagan in 1970 and designed as a 15-item instrument that measured five  
182 conceptual domains of quality of life: 1) material and physical well-being; 2) relationships with  
183 other people; 3) social, community and civic activities; 4) personal development and fulfillment;  
184 5) recreation. A new item was later introduced: independence (the ability to do for yourself). Thus,  
185 for this study we used the 16-item questionnaire since it is considered one of the most powerful  
186 scales for measuring quality of life. A validated questionnaire, quick and easy to use, the QOLS is  
187 scored by summing the items for a total score, ranging from 16 to 112. A higher score indicates a

188 higher quality of life, but a score of 90 is accepted as the average in healthy populations  
189 (Burckhardt et al., 2003).

190 Ultrasound bladder volume calculation was also used in this study since it represents a simple  
191 method to estimate the bladder volume. Every patient was examined with the same ultrasound  
192 scanner, the examination being performed by the same specialist. The sets of data concerning the  
193 volume were obtained using 3D ultrasound equipment, as well as a motorized curved array  
194 transducer (2-5 MHz). The ultrasound probe was fixed about 2 cm on longitudinal and transverse  
195 planes and the bladder diameters (anteroposterior, transverse and superoinferior) were measured.  
196 Based on these data, bladder volume was automatically determined. The normal volume of a  
197 bladder is between 300 and 500 mL, with variations depending on sex, height and weight. The  
198 damage degree from inflammatory causes of the bladder is also evaluated according to the capacity  
199 of the bladder. In other words, the more severe the impairment the smaller the volume of the  
200 bladder (its capacity), the patient having to urinate smaller amounts of urine more frequently.

201 Our research followed the evolution of the symptoms of the patients included in the study, and this  
202 goal can only be achieved by using subjective tests related to symptomatology (not objective tests).  
203 Also, the scales used (PUF, VAS and QOLS-16) are the most important, recommended and used  
204 worldwide in assessing the symptoms of various diseases or treatments.

205

### 206 **2.3. Statistical Analysis**

207 Statistical analysis was performed using EpiInfo and SPSS. The average parameter values,  
208 standard deviations, frequency ranges, and statistical significance tests were calculated using the  
209 Student method (t-test). The Mann Whitney U test (Wilcoxon–Mann–Whitney test) was used to  
210 describe and evaluate pre-instillation parameters of both groups. The Bravais–Pearson correlation

211 coefficient or Pearson product-moment correlation coefficient (PPMCC) were used to calculate an  
212 independent indicator of the units of measurement of the two variables. When the p-value was  
213 below the conventional 5 % ( $p < 0.05$ ) the correlation coefficient was accepted to be statistically  
214 significant.

215

## 216 **2.4. Ethical Statement**

217 Each patient signed an informed consent form prior to inclusion in the study. The study was  
218 conducted in accordance with the World Medical Association Declaration of Helsinki, and in  
219 respect of ethical principles for medical research involving human subjects, approved by the Ethics  
220 Committees of the Emergency Clinical County Hospital of Brasov, of the Central Military  
221 Emergency University Hospital of Bucharest, and of the Emergency Clinical County Hospital of  
222 Targu Mures.

223

## 224 **3. Results**

### 225 **3.1. Patient base-line (pre-instillation) parameters**

226 Pre-instillation demographic parameters were statistically comparable in the two groups. Group I  
227 patients were 19 to 69 years old (average age: 45), while Group II included patients from 35 to 81  
228 years (average age: 52). Gender distribution was 0:30 for Group I and 0:24 for Group II, as  
229 presented in **Table 2**.

230 One patient in Group I, initially included in our study, was later excluded due to an associated  
231 pathology (exclusion criteria) requiring surgery that resulted in placement of a ureteral "JJ" stent,  
232 the presence of the stent being considered as a possible cause of inferior urinary tract symptoms

233 and bladder pain syndrome. The classic Hunner ulcer at cystoscopy was observed in only 7  
234 patients.

235 Each patient received from 4 to 18 instillations (an average of 9 instillations). **Table 3** presents the  
236 characteristics of treatment parameters.

### 237 **3.2. Patients' post-instillation parameters**

#### 238 **3.2.1. Bladder pain**

239 Data was collected prospectively using the pre- and post-treatment questionnaires for pelvic pain,  
240 with a symptom scale for urination and frequency as well as the VAS pain quizzes. For Group I  
241 significant improvement in urinary bladder pain was observed at an average follow-up of 20  
242 months. A statistically significant difference (Mann Whitney U test with  $p=0.0007$ ) in pain  
243 reduction on the VAS was seen from  $7.56\pm 0.41$  (pre-instillation) to  $3.23\pm 0.69$  (post-instillation).  
244 Group II experienced a significant improvement in urinary bladder pain, reported a reduction in  
245 pain-related symptoms on the VAS from  $8.23\pm 0.35$  to  $3.99\pm 1.02$  (Mann Whitney U test with  
246  $p=0.0235$ ).

#### 247 **3.2.2. Daytime urinary frequency**

248 For Group I significant improvement in daytime urinary frequency was observed, being reduced  
249 from  $10.38\pm 1.44$  to  $7.88\pm 1.41$  (Mann Whitney U test with  $p=0.0423$ ). In Group II, no statistically  
250 significant change was found for daytime urinary frequency post-treatment, as a reduction was  
251 reported from  $11.66\pm 1.75$  (pre-treatment) to  $7.62\pm 0.88$  (post-) (Mann Whitney U test with  
252  $p=0.4013$ ).

#### 253 **3.2.3. Quality of life**

254 An important parameter for these patients, quality of life shows significant improvement in Group  
255 I, from  $80\pm 11.2$  to  $96\pm 12.4$ , after treatment (Mann Whitney U test with  $p=0.0322$ ). Group II also

256 experienced significant improvement in the quality of life, from  $78\pm 12.4$  to  $95\pm 11.9$  (Mann  
257 Whitney U test with  $p=0.0487$ ).

#### 258 **3.2.4. Urgency**

259 At the end of treatment, no statistically significant change was observed for urgency among Group  
260 I patients: from  $6.33\pm 0.81$  (pre-treatment) to  $4.02\pm 0.62$  (post-treatment) (Mann Whitney U test  
261 with  $p=0.0693$ ). Group II, however, experienced a significant improvement in urgency, from  
262  $8.57\pm 0.61$  to  $4.9\pm 0.86$  (Mann Whitney U test with  $p=0.0252$ ).

#### 263 **3.2.5. Nocturia**

264 For Group I no statistically significant change was observed regarding nocturia, this parameter  
265 being only slightly modified by treatment, from  $4.10\pm 0.56$  to  $4.07\pm 0.88$  following patient  
266 evaluation (Mann Whitney U test with  $p=0.9075$ ). Group II clearly benefited from treatment,  
267 experiencing significant improvement in nocturia, from  $3.05\pm 0.52$  to  $1.57\pm 0.41$  (Mann Whitney  
268 U test with  $p=0.0243$ ).

#### 269 **3.2.6. Bladder volume change**

270 Treatment with HA instillation had no significant effect on bladder volume in either group. For  
271 Group I, the volume was modified from  $251.2\pm 4.5$  to  $322.5\pm 41.69$  following treatment, and for  
272 Group II from  $185.4\pm 15.55$  to  $258.30\pm 41.21$  (Mann Whitney U test with  $p=0.7782$  for Group I  
273 and  $p=0.3027$  for Group II). Treatment duration for Group I was  $23.4\pm 5.92$  weeks, with patient  
274 monitoring for  $19.9\pm 5.98$  months afterwards. Eighteen patients responded to treatment (60%)  
275 while 12 showed no response (40%). Of those who did not respond, 6 patients (50%) continued to  
276 receive low-dose prophylactic antibiotic therapy. Six patients with OAB and recurrent UTIs were  
277 advised for other therapeutic solutions, including radical surgery with a urinary derivation (ileal  
278 conduit). In Group II, 18 patients (75%) showed complete response to intravesical HA and required

279 no further treatment, while 6 (25%) showed no response. Treatment duration was  $21.9 \pm 8.79$   
280 weeks, with continuous monitoring for  $15.23 \pm 6.88$  months afterwards. Three patients were  
281 oriented towards other therapeutic solutions, including radical surgery with a urinary derivation  
282 (ileal conduit), while 3 others were given intravesical injections of botulinum toxin. Side effects  
283 reported by patients were mild, consisting of bladder irritation (6 patients in Group I and 4 in  
284 Group II); no patient interrupted the treatment.

285 For recurrent UTIs, after applying the t-test significant differences  $p < 0.05$  were found as to  
286 pain score, day-time frequency and life quality while in rest there are no significant differences  
287 ( $p > 0.05$ ). Evolution of data before and after instillation is plotted in **Figure 1** and the patient's  
288 evolution in time is illustrated in **Figure 2**. For IC/PBS interstitial cystitis, we obtained  
289 significant differences ( $p < 0.05$ ) in the case of pain score, life quality, urgency and nocturia  
290 while in rest no significant differences were found. The p values were obtained by applying a  
291 t paired test and the results are plotted in **Figure 3** and **4**.

292

#### 293 **4. Discussion**

294 Recurrent UTIs are common in general gynecology or urology consultation services and affect all  
295 patient age groups (Dason et al., 2011). It is estimated that 50 to 60% of women will experience  
296 at least one episode of urinary infection during their life (Czaja and Hooton, 2006; Epp and  
297 Larochelle, 2010). These infections are more common in women than in men, and the costs of  
298 treatment and care are substantial (Smelov et al., 2016). Also, antibiotic use as a treatment for such  
299 infections is a key driver in reinforcing resistance to antibiotics and has become a substantial  
300 problem in modern medicine in general (Costelloe et al., 2010).

301 Current treatment options include the use of prophylactic antibiotics (Zaha et al., 2019), estrogen  
302 replacement therapy in postmenopausal women (Epp and Larochelle, 2010; Smith et al., 2018;  
303 Vahlensieck et al., 2016), cranberry juice (antioxidants) (Epp and Larochelle, 2010; Jepson et al.,  
304 2012; Yeung et al., 2019) and lifestyle change (Epp and Larochelle, 2010; Jhang and Kuo, 2017)  
305 which involve increased fluid consumption, more frequent emptying of the bladder, especially  
306 before and after sexual activity, supplementary vitamin D (Hertting et al., 2010) plant disinfectants  
307 and plant diuretics (Wagenlehner et al., 2013), acidification of urine (Vahlensieck et al., 2016),  
308 immune active prophylaxis (47), prophylaxis with probiotics (*Lactobacillus* spp.) or D-mannose  
309 (Vahlensieck et al., 2016). Antimicrobial prophylaxis should be considered just following the other  
310 measures due to risk of adverse events and collateral damage. Antimicrobial prophylaxis can be  
311 administered continuously (daily, weekly) for 3 or 6 or 12 months, or as a single post-coital dose  
312 (nitrofurantoin, TMP, TMP/sulfamethoxazole, quinolone or other treatments) (Epp and  
313 Larochelle, 2010; Vahlensieck et al., 2016; Zaha et al., 2019).

314 None of these options have been proven to produce long-term results. In addition, the most  
315 effective treatment (antimicrobial treatment or prophylaxis) is associated with many adverse  
316 events and side effects. Also, patient compliance with the treatment tends to decrease over time  
317 (Epp and Larochelle, 2010; Vahlensieck et al., 2016; Wagenlehner et al., 2013; Beerepoot et al.,  
318 2013). Among the general population, recurrent UTIs cause substantial costs, but on a personal  
319 level this pathology is accompanied by considerable impact on the quality of life (Ciani et al.,  
320 2016). In these cases, gentamicin instillation treatment is also recommended, with good though  
321 questionable results (Ablove et al., 2013; Cox et al., 2017).

322 Due to the poor long-term results obtained with other treatments, a new type of treatment was  
323 suggested based on the recovery of the GAG layer (Lazzeri and Montorsi, 2011). For this purpose,

324 some authors have suggested the use of heparin instillation, with encouraging results in reducing  
325 UTIs recurrences (Vij et al., 2012; Ablove et al., 2013). Also, combined HA and chondroitin  
326 sulfate (CS) instillations appear to produce good results (Ciani et al., 2016; Damiano et al., 2011).  
327 Some publications can be found in the literature on the intravesical use of HA for treatment of  
328 recurrent UTIs. Glycosaminoglycan (GAG) deficiency in the urinary bladder epithelium is a  
329 convincing factor in the etiology of recurrent UTIs (Rovner et al., 2000, Constantinides et al.,  
330 2004; Damiano et al., 2011; Bumbu et al., 2016; Abdel-Daim et al., 2019).  
331 Constantinides et al. (2004) conducted a pilot study on forty women, treated with HA instillations  
332 for recurrent UTIs in 2004, obtaining no recurrence for five months, and 70% of patients had no  
333 recurrence at a one-year follow-up visit. The average time to recurrence was approximately 17  
334 months post-treatment, with high tolerability. Lipovac et al. (2007) practiced HA instillations for  
335 more than 6 months (9 instillations) on 20 women with recurrent UTIs and showed a reduction in  
336 the number of recurrences per person and per year, from statistically significant results, with an  
337 increasing time to recurrence of up to 178 days after treatment. Some authors (Sharifiaghdas and  
338 Hamzehi, 2010) conducted a study on thirty women with recurrent UTIs and reported good results,  
339 with no recurrence 6 months after treatment. Other authors have also reported good results with  
340 HA instillations, but those studies were conducted only on small groups of patients (Vedanayagam  
341 et al., 2013, Nightingale et al., 2018).

342 We recruited 30 patients with documented recurrent UTIs who were on prophylactic antibiotic  
343 therapy during the study period. On average, each patient received 9 intravesical HA instillations  
344 over 23 weeks. At a follow-up visit an average of 20-months post-treatment, 60% of our patients  
345 demonstrated complete response and interrupted the prophylactic antibiotic treatment. Of those  
346 who did not respond to treatment, 20% continued the low-dose prophylactic treatment. Six patients



347 with OAB and recurrent urinary tract infections were re-oriented to other therapeutic solutions.  
348 Also, after the HA instillations, patients with recurrent UTIs showed many other statistically  
349 significant improvements: bladder pain, day-time frequency and quality of life. The other  
350 parameters – urgency, nocturia and bladder volume change – showed no significant post-treatment  
351 change. Side effects reported by patients were mild: bladder irritation (6 patients) with no  
352 interruption of treatment.

353 BPS/IC is a condition affecting both women and men, with no variation according to race or  
354 ethnicity (Clemens et al., 2007). Its prevalence is difficult to appreciate as no clear definition or  
355 criteria for diagnosis can be established; it is thus considered to be an underdiagnosed affection  
356 (Berry et al., 2011; Mullins et al., 2015) and is estimated to affect from 2.7% to 6.53% of persons  
357 aged 18 or older (Berry et al., 2011).

358 Recognized as difficult to establish, the diagnosis is based in particular on the symptoms described  
359 by the patient after eliminating other causes that may induce symptoms (Clemens et al., 2007;  
360 Hanno et al., 2010). Though the term “interstitial cystitis” is frequently reserved for cases of BPS  
361 associated with typical cystoscopic and histologic findings, the term IC is primarily used to  
362 describe inflammatory changes localized in the bladder. The term BPS was initially used to  
363 describe patients with painful bladder symptoms, though such symptoms may also have other  
364 causes. However, in the absence of other causes that might help to explain these manifestations  
365 (van de Merwe et al., 2008; Han et al., 2018) the two terms are often used together to describe a  
366 pain syndrome that is mainly located in the bladder and pelvis in relation to bladder filling.  
367 Symptoms are numerous and unspecific. It is recognized that patients generally describe pain that  
368 is localized in the bladder, pelvis and genital organs, and that is accompanied by urinary symptoms  
369 (dysuria, frequency), in the absence of proven urinary infection or other obvious pathologies (van

370 de Merwe et al., 2008; Hanno et al., 2010; Mullins et al., 2015; Han et al., 2018). However, the  
371 diagnosis is difficult to establish because BPS/IC can be confused with many other pathologies  
372 (Leppilahti et al., 2002; van de Merwe et al., 2008).

373 Despite all the research, clinical trials and repeated attempts made to understand the mechanism  
374 of these conditions, BPS/IC is still insufficiently known and effective treatment remains under  
375 debate. Numerous problems have been caused by the fact that, besides pathological mechanisms  
376 of the bladder, it supports the existence of other possible mechanisms located outside of the bladder  
377 (pelvic or systemic, including alterations of the central nervous system in some patients) that may  
378 be determinant for BPS/IC (Mullins et al., 2015; Engeler et al., 2018). To further complicate  
379 matters, epidemiological studies have shown that BPS/IC is commonly associated with many other  
380 chronic conditions which may be caused by the same physio-pathological mechanism (systemic  
381 mechanism) and that the essential problem might not be located in the bladder. Frequent  
382 associations are with fibromyalgia, irritable bowel syndrome, chronic fatigue syndrome and  
383 chronic widespread pain (Mullins et al., 2015). This organ-centric terminology places BPS/IC  
384 within the overall scope of chronic pelvic pain syndromes (CPPS), which also include prostate,  
385 gynecological and bowel pain syndromes. The European Association of Urology no longer  
386 recommends the use of terms such as BPS/IC (or other types of pain syndromes) and now groups  
387 them all together under the more generally diagnostic term Chronic Pelvic Pain Syndrome (CPPS)  
388 (Engeler et al., 2018), though this practice is not universally accepted.

389 Though consensus and convincing data are lacking, certain risk factors for BPS/IC are nevertheless  
390 recognized: genetics, psychological state, recurrent physical trauma and endocrine factors (Engeler  
391 et al., 2018). In urological clinical practice, BPS/IC and recurrent UTIs can be difficult conditions  
392 to manage. According to the European Association of Urology, BPS/IC is described as a chronic,

393 annoying condition of the bladder (Engeler et al., 2018) and the so-called Hunner ulcer may be a  
394 typical cystoscopic finding in from 10 to 50% of IC patients, which is why the absence of Hunner  
395 lesions is not a criterion for exclusion of BPS/IC (Hanno et al., 2010).

396 Diagnosis is based primarily on patient symptoms, after exclusion of other causes. Investigations  
397 directed towards differential diagnosis are recommended, but other tests are also needed:  
398 cystoscopy, urodynamics, pathology exam (during cystoscopy), potassium test (Hanno et al., 2010;  
399 van de Merwe et al., 2008; Grigorescu et al., 2016; Engeler et al., 2018). Biomarkers will be  
400 recommended in the future as they can furnish important data, especially an anti-proliferative  
401 factor (Grigorescu et al., 2016).

402 Cystoscopic bladder biopsy studies revealed clear defects in the urothelial GAG layer, with  
403 secondary occurrence of submucosal exposure to toxic substances in the urine, with cytotoxic  
404 effect (Constantinides et al., 2004; Logadottir et al., 2004; Sanchez-Freire et al., 2011; Stav and  
405 Lindner, 2011; Engeler et al., 2018). Not without significance is the fact that many studies show  
406 that BPS/IC has a significant impact on quality of life, with consequent depression, anxiety,  
407 impaired emotional functioning, insomnia and fatigue, including change of profession due to pain  
408 (Bosch and Bosch, 2014; Chuang et al., 2015; Engeler et al., 2018). Different conservative  
409 therapies have been suggested for BPS/IC: physiotherapy, behavioral modification, stress  
410 reduction, dietary manipulation, all with different and inconstant results (van de Merwe et al.,  
411 2008; Hanno et al., 2010; Engeler et al., 2018).

412 Types of surgical and medical treatment have been previously described in the literature for this  
413 condition with varying results (Porru et al., 1997; Constantinides et al., 2004; Iavazzo et al., 2007;  
414 Fall et al., 2008; Gajewski and Al-Zahrani, 2011; Engeler et al., 2018; Han et al., 2018). These  
415 include oral hydroxysin, pentosan, amitriptyline, L-arginine, methotrexate, montelukast,

416 prostaglandins, cyclosporin A, oxybutynin, duloxetine, intravesical pentosan, intravesical  
417 *Botulinum toxinum* type A, intravesical anesthetics, intravesical heparin, intravesical *Bacillus*  
418 Calmette-Guerin, intravesical silver nitrate, intravesical chondroitin sulphate, intravesical  
419 dimethylsulfoxide (DMSO), intravesical cloropactin WCS 90, intravesical vanilloids, intravesical  
420 HA and many other possible substances (many of which have no demonstrated efficacy). Surgical  
421 interventions include bladder distention, hyperbaric oxygen, epidural pain pumps, sacral  
422 neuromodulation, sympathetic denervation, transurethral resection and electrocoagulation or  
423 major reconstructive surgery (Magnus et al., 2008; Fall et al., 2008; van de Merwe et al., 2008;  
424 Hanno et al., 2010; Gajewski and Al-Zahrani, 2011; Engeler et al., 2018; Han et al., 2018).

425 Instillation treatment with HA has found its logical explanation via attempted restoration of the  
426 GAG layer, which is affected primarily in this pathology, the short-term response being favorable  
427 in many situations. Many authors have published studies of different groups of patients, with  
428 differing results. In patients with BPS/IC, Iavazzo et al. (2007) have shown a varying but positive  
429 response ranging from 30 to 73 %, when instillation with HA was used. Kallestrup et al. (2005)  
430 observed a decrease in nocturia and pain of 40 and 30 %, respectively, in 65 % of responders to  
431 therapy with minimal side effects and with a decrease in analgesic use after 3 months of HA  
432 instillation treatment. In 2015, an interesting study by Rooney et al. (2015) highlighted the  
433 mechanisms through which HA instillation is efficient in BPS/IC treatment, proving that HA  
434 significantly decreases induced cytokine secretion (4-5 folds increase), increases sulphated GAG  
435 production (2-fold increase) and decreases trans-epithelial permeability. They also suggested that  
436 HA pathway is a clinical target and potential treatment vector (Rooney et al., 2015). In a study  
437 from 2016, Pyo and Cho (2016) concluded that HA instillations (alone or in combination with CS)  
438 have good and significant effects on pain symptoms, quality of life and other outcomes. The study

439 by Riedl et al. (2008) is probably the most extensive for this purpose (in terms of number of  
440 patients): one hundred twenty-six patients with BPS/IC were enrolled. The authors observed a  
441 VAS score of 8.5 which decreased to 3.5 after therapy; 55 % of patients remained with no or  
442 minimal bladder symptoms and 84% reported significant post-treatment improvement in their  
443 quality of life. In addition, they suggested that the HA instillations would have a good response  
444 rate if a modified potassium test showed a positive result (sign of a urine-tissue barrier disorder).  
445 Some authors have suggested administration of HA with EMDA (electromotive drug  
446 administration) as this technique appears to improve treatment efficacy (Gülpınar et al., 2014).  
447 Another contradiction is observed concerning different regimens of intravesical HA instillation for  
448 patients with BPS/IC. Lai et al. found no significant difference in therapeutic effect between two  
449 groups of regimens, both showing significant improvement in symptom scores and quality of life  
450 (Lai et al., 2013). All these studies have proven that HA treatment acts on the GAG barrier, not  
451 only by restoring it momentarily, but with its ability to stimulate the formation of new cells to  
452 regenerate the GAG layer.

453 24 patients with BPS/IC were recruited for our study according to the EAU Diagnostic Criteria.  
454 On average, each patient received 9 intravesical HA instillations over nearly 22 weeks. After a  
455 follow-up period of 15 months, 75 % of these patients demonstrated a complete response. Six of  
456 them (25 %) did not respond to this treatment and thus other therapeutic solutions were prescribed,  
457 including radical surgery with a urinary derivation (n=3) and intravesical *Botulinum* toxin type A  
458 (n=3).

459 Some patients with BPS/IC showed other improvements following the HA instillations;  
460 statistically significant improvements were observed in pain, urgency, nocturia and quality of life.  
461 Other parameters, such as day-time frequency and bladder volume were not significantly modified.

462 Side effects reported by patients were mild and consisted of bladder irritation (4 patients), with no  
463 interruption of treatment. Due to the reduced number of patients with Hunner ulcer, we cannot  
464 establish whether the evolution of those cases was of a different type.

465 Summary data of these studies are presented in **Table 4**. Compared with the previous studies  
466 mentioned, the present research addresses in a more complex way the effects of HA in the  
467 evolution of both pathologies using several specific evaluation tools (VAS, quality of life), the  
468 evaluation of the specific symptoms (nocturia, bladder volume change) along with the fact that the  
469 evolution of patients after the end of treatment is followed for a longer period.

470 Our research is not intended as a comparative study nor a non-inferiority one, but followed the  
471 long-term evolution of patients with two different conditions, who can also benefit from this  
472 treatment. The two pathologies evolve with violent symptoms that do not decrease or disappear  
473 without treatment. Therefore, no control group could not be included in the study nor in any study  
474 of this type. On the other hand, our research focused primarily on assessing how long-term  
475 symptoms improved, and patients with such conditions could not be left untreated for 2 years (the  
476 duration of this research). Instillation treatment with HA was initially tested for BPS / IC patients,  
477 then expanded as a possible recommendation for those with urinary infections.

478 Women of any age are at increased risk of recurrent UTIs at an alarming rate. Treatment methods  
479 recommended and used around the world are still questionable when it comes to long-term  
480 effectiveness, as the clear mechanisms by which urinary tract infection appears are not yet  
481 elucidated. However, it is clear that we must first try to control the predisposing factors and call  
482 for patient behavioral change. Non-antimicrobial measures are important because they tend to  
483 reduce the use of antibiotic prophylaxis. In contrast, BPS/IC are a chronic and debilitating disease  
484 that clearly affect quality of life in all areas. In most studies, this condition is underdiagnosed due

485 to a lack of consensus on diagnosis, evaluation and treatment. Moreover, BPS/IC tend to be  
486 frustrating and difficult to manage, both for patients and doctors, creating a feeling of  
487 dissatisfaction with the quality of care.

488 One possible research limitation is the limited number of patients, however interstitial cystitis is a  
489 disease not very commonly diagnosed and treatments are not yet standardized. In this sense, most  
490 studies dealing with interstitial cystitis involve a low number of patients. We believe that, although  
491 our work is a multicenter study conducted in 3 large universities, the number of patients who could  
492 be evaluated and monitored is considered low.

493

## 494 **5. Conclusions**

495 HA instillation is an effective GAG substitution therapy in patients with recurrent UTIs and  
496 BPS/IC resistant to other types of therapy, an effect that persists over a non-negligible period of  
497 time post-treatment. Until the biggest problems with BPS/IC (controversies concerning definition,  
498 etiology, molecular mechanisms, pathology and prevalence) are resolved, our study demonstrates  
499 that intravesical HA instillations may be considered as an important component in the therapeutic  
500 strategy for optimal results in uncomplicated recurrent UTIs and BPS/IC over a long period. A  
501 longer patient observation period and enrollment in controlled, double-blind studies of several  
502 cases will be necessary to confirm the long-term efficacy of the product in these two clinically  
503 challenging pathologies that severely affect the patient's quality of life.

504

## 505 **Ethical Statement**

506 Each patient signed an informed consent form prior to inclusion in the study. The study was  
507 conducted in accordance with the World Medical Association Declaration of Helsinki, and in

508 respect of ethical principles for medical research involving human subjects, approved by the Ethics  
509 Committees of the Emergency Clinical County Hospital of Brasov, of the Central Military  
510 Emergency University Hospital of Bucharest, and of the Emergency Clinical County Hospital of  
511 Targu Mures.

512 **Disclosure Statement:** The authors declare no conflict of interest.

513 **Contribution:** All authors had equal contribution to this paper.

514 **Funding:** This research received no external funding

515

## 516 **References**

517 Abdel-Daim MM, El-Tawil OS, Bungau SG, Atanasaov AG. Applications of Antioxidants in  
518 Metabolic Disorders and Degenerative Diseases: Mechanistic Approach. *Oxid Med Cell Longev*  
519 2019; 2019:ID 4179676. <https://doi.org/10.1155/2019/4179676>

520 Ablove T, Patankar M, Seo S. Prevention of recurrent urinary tract infections by intravesical  
521 administration of heparin: a pilot study. *Ther Adv Urol* 2013; 5(6):303-9.

522 Abrams P, Hashim H, Tomson C, Macgowan A, Skews R, Warren K. The use of intravesical  
523 gentamicin to treat recurrent urinary tract infections in lower urinary tract dysfunction. *Neurourol*  
524 *Urodyn* 2017; 36(8):2109-2116.

525 Aydin A, Ahmed K, Zaman I, Khan MS, Dasgupta P. Recurrent urinary tract infections in  
526 women. *Int Urogynecol J* 2015; 26(6):795-804.

527 Beerepoot MA, Geerlings SE, van Haarst EP, van Charante NM, ter Riet G. Nonantibiotic  
528 prophylaxis for recurrent urinary tract infections: a systematic review and meta-analysis of  
529 randomized controlled trials. *J Urol* 2013; 190:1981-9.



530 Berry SH, Elliott MN, Suttorp M, Bogart LM, Stoto MA, Eggers P, Nyberg L, Clemens JQ.  
531 Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the  
532 United States. *J Urol* 2011; 186(2):540-4.

533 Bosch PC, Bosch DC. Treating interstitial cystitis/bladder pain syndrome as a chronic disease.  
534 *Rev Urol* 2014; 16(2):83-7.

535 Brewer ME, White WM, Klein FA, Klein LM, Waters WB. Validity of Pelvic Pain, Urgency,  
536 and Frequency questionnaire in patients with interstitial cystitis/painful bladder syndrome.  
537 *Urology* 2007; 70(4):646-9.

538 Bumbu A, Pasca B, Tit DM, Bungau S, Bumbu G, The effects of soy isoflavones and  
539 hormonal replacing therapy on the incidence and evolution of postmenopausal female urinary  
540 incontinence. *Farmacia* 2016; 64(3):419-22.

541 Burckhardt CS, Anderson KL. The Quality of Life Scale (QOLS): Reliability, Validity, and  
542 Utilization. *Health Qual Life Outcomes* 2003; 1:60.

543 Burckhardt CS, Jones KD. Adult measures of pain: The McGill Pain Questionnaire (MPQ),  
544 Rheumatoid Arthritis Pain Scale (RAPS), Short-Form McGill Pain Questionnaire (SF-MPQ),  
545 Verbal Descriptive Scale (VDS), Visual Analog Scale (VAS), and West Haven-Yale  
546 Multidisciplinary Pain Inventory (WHYMPI). *Arthritis Rheum* 2003; 49:S96-104.

547 Burkman RT. Chronic pelvic pain of bladder origin: epidemiology, pathogenesis and quality  
548 of life. *J Reprod Med* (2004) 49:225-9.

549 Chuang YC, Weng SF, Hsu YW, Huang CLC, Wu MP. Increased risks of healthcare-seeking  
550 behaviors of anxiety, depression and insomnia among patients with bladder pain  
551 syndrome/interstitial cystitis: a nationwide population-based study. *Int Urol Nephrol* 2015; 47:275.

552 Ciani O, Arendsen E, Romancik M, Constantini E, Di Blase M, Morgia G, et al. Intravesical  
553 administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment  
554 of female recurrent urinary tract infections: a European multicentre nested case-control study.  
555 *BMJ Open* 2016; 6:e009669.

556 Clemens JQ, Link CL, Eggers PW, Kusek JW, Nyberg LMJr, McKinlay JB. BACH Survey  
557 Investigators. Prevalence of painful bladder symptoms and effect on quality of life in black,  
558 Hispanic and white men and women. *J Urol* 2007; 177(4):1390-4.

559 Constantinides C, Manousakas T, Nikolopoulos P, Stanitsas A, Haritopoulos K, Giannopoulos  
560 A. Prevention of recurrent bacterial cystitis by intravesical administration of hyaluronic acid: a  
561 pilot study. *BJU Int* 2004; 93:1262-6.

562 Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. Effect of antibiotic prescribing in  
563 primary care on antimicrobial resistance in individual patients: systematic review and meta-  
564 analysis. *BMJ* 2010; 18:340:c2096.

565 Cox L, He C, Bevins J, Clemens JQ, Stoffel JT, Cameron AP. Gentamicin bladder instillations  
566 decrease symptomatic urinary tract infections in neurogenic bladder patients on intermittent  
567 catheterization. *Can Urol Assoc J* 2017; 11(9):E350-E354.

568 Czaja CA, Hooton TM. Update on acute uncomplicated urinary tract infection in women.  
569 *Postgrad Med* 2006; 119:39-45.

570 Daha KL, Riedl CR, Lazar D, Simak R, Pflüger H. Effect of intravesical glycosaminoglycan  
571 substitution therapy on bladder pain syndrome/interstitial cystitis, bladder capacity and potassium  
572 sensitivity. *Scand J Urol* 2008; 8:369-72.

573 Daha LK, Riedl CR, Hohlbrugger G, Knoll M, Engelhardt PF, Pflüger H. Comparative  
574 assessment of maximal bladder capacity, 0.9% NaCl vs. 0.2 M KCl, for the diagnosis of interstitial  
575 cystitis: a prospective controlled study. *J Urol* 2003; 170:807-9.

576 Damiano R, Cicione A. The role of sodium hyaluronate and sodium chondroitin sulphate in  
577 the management of bladder disease. *Ther Adv Urol* 2011; 3(5):223-32.

578 Damiano R, Quarto G, Bava I, Ucciero G, De Domenico R, Palumbo MI, Autorino R.  
579 Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid  
580 and chondroitin sulphate: a placebo-controlled randomised trial. *Eur Urol* 2011; 59(4):645-51.

581 Dason S, Dason JT, Kapoor A. Guidelines for the diagnosis and management of recurrent  
582 urinary tract infection in women. *Can Urol Assoc J* 2011; 5(5):316-22.

583 Engeler D, Baranowski AP, Borovicka J, Cottrell AM, Dinis-Oliveira P, Elneil S, et al. EAU  
584 Guidelines on Chronic Pelvic Pain 2018. <http://uroweb.org/guideline/chronic-pelvic-pain/> (last  
585 accessed November 2018)

586 Epp A, Larochelle A. Recurrent Urinary Tract Infection. *J Obstetrics Gynaecol Can* 2010;  
587 32(11):1082-90.

588 Fall M, Oberpenning F, Peecker R. Treatment of bladder pain syndrome/interstitial cystitis  
589 2008: can we make evidence-based decisions? *Eur Urol* 2008; 54:65-75.

590 Foster RTSr. Uncomplicated urinary tract infections in women. *Obstet Gynecol Clin North*  
591 *Am* 2008; 35(2):235-48.

592 Foxman B, Gillespie B, Koopman J, Zhang L, Palin K, Tallman P, et al. Risk factors for  
593 second urinary tract infection among college women. *Am J Epidemiol* 2000; 151:1194-205.

594 Foxman B. Epidemiology of urinary tract infections: incidence, morbidity and economic  
595 costs. *Am J Med* 2002; 113(1A):5S–13S.

596 Gajewski JB, Al-Zahrani AA. The long-term efficacy of sacral neuromodulation in the  
597 management of intractable cases of bladder pain syndrome: 14 years of experience in one centre.  
598 *BJU Int* 2011; 107(8):1258-64.

599 Grigorescu B, Powers K, Lazarou G. Update on Urinary Tract Markers in Interstitial  
600 Cystitis/Bladder Pain Syndrome. *Female Pelvic Med Reconstr Surg* 2016; 22(1):16-23.

601 Gülpınar O, Haliloğlu AH, Gökce, Mİ, Arıkan N. Instillation of hyaluronic acid via  
602 electromotive drug administration can improve the efficacy of treatment in patients with interstitial  
603 cystitis/painful bladder syndrome: A randomized prospective study. *Korean J Urol* 2014;  
604 55(5):354-9.

605 Gupta K, Stamm WE. Pathogenesis and management of recurrent urinary tract infections in  
606 women. *World J Urol* 1999; 17:415-20.

607 Han E, Nguyen L, Sirls L, Peters K. Current best practice management of interstitial  
608 cystitis/bladder pain syndrome. *Therap Adv Urol* 2018; 10(7):197-211.

609 Hanno P, Lin A, Nordling J, Nyberg L, van Ophoven A, Ueda T, Wein A. Bladder pain  
610 syndrome international consultation on incontinence. *Neurourol Urodyn* 2010; 29:191-8.

611 Hertting O, Holm A, Lüthje P, Brauner H, Dyrdak R, Jonasson AF, et al. Vitamin D Induction  
612 of the Human Antimicrobial Peptide Cathelicidin in the Urinary Bladder. *PLoS One* 2010;  
613 5(12):e15580.

614 Hooton TM. Recurrent urinary tract infection in women. *Int J Antimicrob Agents* 2001;  
615 17:259-68.

616 Hurst RE, Roy JB, Min KW, Veltri RW, Marley G, Patton K, et al. A deficit of chondroitin  
617 sulfate proteoglycans on the bladder uroepithelium in interstitial cystitis. *Urology* 1996; 48(5):817-  
618 21.

619 Iavazzo C, Athanasiou S, Pitsouni E, Falagas ME. Hyaluronic acid: an effective alternative  
620 treatment of interstitial cystitis, recurrent urinary tract infections, and hemorrhagic cystitis. *Eur*  
621 *Urol* 2007; 51:1534-41.

622 Jensen MP, Chen C, Brugger AM. Interpretation of visual analog scale ratings and change  
623 scores: a reanalysis of two clinical trials of postoperative pain. *J Pain* 2003; 4:407-14.

624 Jensen MP, Karoly P, Braver S. The measurement of clinical pain intensity: a comparison of  
625 six methods. *Pain* 1986; 27:117-26.

626 Jepson RG, Williams G, Craig JC. Cranberries for preventing urinary tract infections.  
627 *Cochrane Database Syst Rev* 2012; CD001321.

628 Jhang JF, Kuo HC. Recent advances in recurrent urinary tract infection from pathogenesis and  
629 biomarkers to prevention. *Ci Ji Yi Xue Za Zhi* 2017; 29(3):131-7.

630 Kallestrup EB, Jorgensen SS, Nordling J, Hald T. Treatment of interstitial cystitis with  
631 Cystistat: a hyaluronic acid product. *Scand J Urol Nephrol* 2005; 39(2):143-7.

632 Kaufman JE, Anderson K, Parsons CL. Inactivation of anti-adherence effect of bladder surface  
633 glycosaminoglycans as possible mechanism for carcinogenesis. *Urology* 1987; 30:255-8.

634 Lai MC, Kuo YC, Kuo HC. Intravesical hyaluronic acid for interstitial cystitis/painful bladder  
635 syndrome: a comparative randomized assessment of different regimens. *Int J Urol* 2013;  
636 20(2):203-7.

637 Lazzeri M, Montorsi F. The therapeutic challenge of “chronic cystitis”: search well, work  
638 together, and gain results. *Eur Urol* 2011; 60:78-80.

639 Leppilahti M, Hellstrom P, Tammela TL. Effect of diagnostic hydrodistension and four  
640 intravesical Hyaluronic acid instillations on bladder ICAM-1 intensity and association of ICAM-  
641 1 intensity with clinical response in patients with interstitial cystitis. *Urology* 2002; 60:46-51.

642 Lipovac M, Kurz C, Reithmayr F, Verhoeven HC, Huber JC, Imhof M. Prevention of recurrent  
643 bacterial urinary tract infections by intravesical instillation of hyaluronic acid. *Int J Gynaecol*  
644 *Obstet* 2007; 96(3):192-5.

645 Logadottir YR, Ehren I, Fall M, Wiklund NP, Peeker R. Intravesical nitric oxide production  
646 discriminates between classic and nonulcer interstitial cystitis. *J Urol* 2004; 171(3):1148-51.

647 Magnus F, Oberpenning F, Peeker R. Treatment of Bladder Pain Syndrome / Interstitial  
648 Cystitis 2008: Can we make evidence-based decisions? *Eur Urol* 2008; 54(1):65-78.

649 Mullins C, Bavendam T, Kirkali Z, Kusek JW. Novel research approaches for interstitial  
650 cystitis/bladder pain syndrome: thinking beyond the bladder. *Transl Androl Urol* 2015; 4(5):524-  
651 33.

652 Nightingale G, Shehab Q, Kandiah C, Rush L, Rowe-Jones C, Philips CH. The effect of  
653 intravesical instillations with Hyaluronic Acid on sexual dysfunction in women with recurrent  
654 urinary tract infections (RUTI). *Eur J Obstetrics Gynecol Reproductive Biol* 2018; 221:105-8.

655 Oravisto KJ. Epidemiology of interstitial cystitis. *Ann Chir Gynaecol Fenn* 1975; 64:75-7.

656 Parsons CL, Dell J, Stanford EJ, Bullen M, Kahn BS, Waxell T, Koziol JA. Increased  
657 prevalence of interstitial cystitis: previously unrecognized urologic and gynecologic cases  
658 identified using a new symptom questionnaire and intravesical potassium sensitivity. *Urology*  
659 2002; 60(4):573-8.

660 Parsons CL, Lilly JD, Stein P. Epithelial dysfunction in nonbacterial cystitis (interstitial  
661 cystitis). *J Urol* 1991; 145(4):732-5.

662 Parsons CL. Potassium sensitivity test. *Tech Urol* 1996; 2:171-3.

663 Porru D, Campus G, Tudino D, Valdes E, Vespa A, Scarpa RM, Usai E. Results of treatment  
664 of refractory interstitial cystitis with intravesical hyaluronic acid. *Urol Int* 1997; 59:26-9.

665 Pyo JS, Cho WJ. Systematic Review and Meta-Analysis of Intravesical Hyaluronic Acid and  
666 Hyaluronic Acid/Chondroitin Sulfate Instillation for Interstitial Cystitis/Painful Bladder  
667 Syndrome. *Cell Physiol Biochem* 2016; 39:1618-25.

668 Raymond I, Vasdev N, Ferguson J, Haskin M, Davis, L, Hasan, T S. The clinical effectiveness  
669 of intravesical sodium hyaluronate (cystistat®) in patients with interstitial cystitis/painful bladder  
670 syndrome and recurrent urinary tract infections. *Curr Urol* 2012; 6(2):93-8.

671 Riedl CR, Engelhardt PF, Daha KL, Morakis N, Pflüger H. Hyaluronan treatment of  
672 interstitial cystitis/painful bladder syndrome. *Int Urogynecol J Pelvic Floor Dysfunct* 2008;  
673 19(5):717-21.

674 Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. *Am J*  
675 *Med* 2002; 113(1A):14-9.

676 Rooney P, Srivastava A, Watson L, Quinlan LR, Pandit A. Hyaluronic acid decreases IL-6  
677 and IL-8 secretion and permeability in an inflammatory model of interstitial cystitis. *Acta*  
678 *Biomater* 2015; 19:66-75.

679 Rovner E, Propert KJ, Bresinger C, Wein AJ, Foy M, Kirkemo A. et al. Treatment used in  
680 women with interstitial cystitis: the interstitial cystitis data base (ICDB) study experience. The  
681 Interstitial Cystitis Data Base Study Group. *Urology* 2000; 56(6):940-5.

682 Sanchez-Freire V, Blanchard MG, Burkhard FC, Kessler TM, Kellenberger S, Monastyrskaya  
683 K. Acid-sensing channels in human bladder: expression, function and alterations during bladder  
684 pain syndrome. *J Urol* 2011; 186(4):1509-16.

685 Scholes D, Hooton TM, Roberts PL, Stapleton AE, Gupta K, Stamm WE. Risk factors for  
686 recurrent urinary tract infection in young women. *J Infect Dis* 2000; 182:1177-82.

687 Sharifiaghdas F, Hamzehi Esfahani N. UP-2.62: Intravesical instillation of hyaluronic acid in  
688 the treatment of recurrent urinary tract infection in women. *Urology* 2010; 76(3):S102.

689 Smelov V, Naber K, Bjerklund Johansen TE. Improved Classification of Urinary Tract  
690 Infection: Future Considerations. *Euro Urol Supp* 2016; 15:71-80.

691 Smith AL, Brown J, Wyman JF, Berry A, Newman DK, Stapleton AE. Treatment and  
692 Prevention of Recurrent Lower Urinary Tract Infections in Women: A Rapid Review with Practice  
693 Recommendations. *J Urol* 2018; 5347(18):43408-8.

694 Stav K, Lindner A. Interstitial cystitis/painful bladder syndrome: a comprehensive review of  
695 the current literature. *Harefuah* 2011; 150:168-74.

696 Tit DM, Pallag A, Iovan C, Furu G, Furu C, Bungau S. Somatic-vegetative symptoms  
697 evolution in postmenopausal women treated with phytoestrogens and hormone replacement  
698 therapy. *Iran J Public Health* 2017; 46(11):1128-1134.

699 Vahlensieck W, Perepanova T, Bjerklund Johansen TE, Tenke P, Naber KG, Wagenlehner  
700 FME. Management of uncomplicated recurrent urinary tract infections. *Eur Urol Supp* 2016;  
701 15(4):95-101.

702 Van de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, Cervigni M, Kurosch L, et  
703 al. Diagnostic Criteria, Classification, and Nomenclature for Painful Bladder Syndrome/Interstitial  
704 Cystitis: An ESSIC Proposal. *Eur Urol* 2008; 53(1):60-7.

705 Vedanayagam M, Brewin J, Briggs K, Salahia G, Hammadeh M. The role of hyaluronic acid  
706 in the management of uncomplicated recurrent female urinary tract infections: Literature review  
707 and practical experience. *J Clin Urol* 2013; 6:243-8.

708 Vij M, Srikrishna S, Cardozo L. Interstitial cystitis: diagnosis and management. *Eur J Obstet  
709 Gynecol Reprod Biol* 2012; 161(1):1-7.



710 Wagenlehner FM, Vahlensieck W, Bauer HW, Weidner W, Piechota HJ, Naber, KG.  
711 Prevention of recurrent urinary tract infections. *Minerva Urol Nefrol* 2013; 65:9-20.

712 Yeung AWK, Tzvetkov N, El-Tawil OS, Bungau SG, Abdel-Daim MM, Atanasov AG.  
713 Antioxidants: scientific literature landscape analysis. *Oxid Med Cell Longev* 2019; 2019:ID  
714 8278454. <https://doi.org/10.1155/2019/8278454>

715 Zaha DC, Bungau S, Aleya S, Tit DM, Vesa CM, Popa AR., Carmen P, Maghiar OA, Bratu  
716 OG, Furu C, Moleriu RD, Petre I, Aleya L. What antibiotics for what pathogens? The  
717 sensitivity spectrum of isolated strains in an intensive care unit. *Sci Total Environ* 2019; 687:118-  
718 27. <https://doi.org/10.1016/j.scitotenv.2019.06.076>

719 Zhong YH, Fang Y, Zhou JZ, Tang Y, Gong SM, Ding Q. Effectiveness and safety of patient  
720 initiated single-dose versus continuous low-dose antibiotic prophylaxis for recurrent urinary tract  
721 infections in postmenopausal women: a randomized controlled study. *J Int Med Res* 2011;  
722 39:2335-43.

723

724

725

726

727

728

729

730

731

732 **List of figures**

733 **Figure 1.** Symptomatic response and the evolution of symptomatology according to the scales in  
734 patients of Group I treated with HA instillation – 50 mL/ 40 mg in the case of recurrent urinary  
735 tract infections. (N/10 represents the average of the obtained values, having a range of possible  
736 values between 0 and 10, where 0 means the least (the minimum value) and 10 means the most  
737 (the maximum value).

738 **Figure 2.** Symptomatic response and the evolution of symptomatology according to the tested  
739 time points. (N/10 represents the average of the obtained values, having a range of possible values  
740 between 0 and 10, where 0 means the least (the minimum value) and 10 means the most (the  
741 maximum value).

742 **Figure 3.** Symptomatic response and the evolution of symptomatology according to the scales in  
743 patients of Group II (with PBS / IC) treated with HA instillation – 50 mL/ 40 mg for the case of  
744 painful bladder syndrome/ interstitial cystitis. (N/10 represents the average of the obtained values,  
745 having a range of possible values between 0 and 10, where 0 means the least (the minimum value)  
746 and 10 means the most (the maximum value).

747 **Figure 4.** The symptomatology evolution in four-time moments for the painful bladder syndrome/  
748 interstitial cystitis. (N/10 represents the average of the obtained values, having a range of possible  
749 values between 0 and 10, where 0 means the least (the minimum value) and 10 means the most  
750 (the maximum value).




Figure 1.




Figure 2.




Figure 3.




Figure 4.

Table 1. Most used instilling preparations for the treatment of BPS/IC commercialized in Europe

Intra-vesical agent/ active substance	Trade name	Composition
HA	Cystistat®	40 mg HMW-HA (0.08 %) / 50 mL
	Hyacyst®	40 / 120 mg HA (0.08 / 0.24 %) / 50 mL
	Uromac®	100 mg LMW HA (0.2 %) / 50 mL
CS	Gepan instill®	80 mg CS (0.2 %) / 40 mL
	Uracyst®	400 mg CS (2 %) / 20 mL
HA/CS	Ialuril®	800 mg LMW-HA (1.6 %)/1 g CS (2%)/50 mL
DMSO	Rimso-50®	27 g DMSO (5.4 %) / 50 mL
PPS	Cyst-u-ron®	300 mg PPS (1 %) / 30 mL

HA – sodium hyaluronate (hyaluronic acid), CS – Chondroitin sulphate, PPS – Pentosan polysulphate sodium, DMSO – Dimethyl sulfoxide, HMW – High molecular weight, LMW – Low molecular weight

Table 2. Pre-instillation parameters of patients (Mann Whitney U test)

Characteristics of patients	Group I (UTI)	Group II (BPS/IC)	p
Male:Female	0:30	0:24	-
Current age (years)	53.25±4.8	56.50±4.74	0.9633
Age at initial presentation (years)	45.28±4.72	52.00±4.52	0.4521
Urodynamic findings	DO (n=12), N (n=18)	DO (n=0), N (n=24)	-
Previous treatments			
Over-distention	3	12	-
Urethral dilatations	6	0	0.5745
Anticholinergics	3	3	1.0000
Botulinum toxin type A	3	3	0.3587
Patients on antibiotics, n	30 (100 %)	0 (0 %)	-
Pre-instillation bladder volume (mL)	251.2 ±34.5	185.4±15.55	-
Pre-instillation daytime frequency (N)	10.38±1.44	11.66±1.75	0.9840
Pre-instillation urgency (N/10)	6.33±0.81	8.57±0.61	0.9224
Pre-instillation pain score (N/10)	7.56±0.41	8.23±0.35	0.0568
Pre-instillation continence (N)	C (n=21), IC (n=9)	C (n=24), IC (n=0)	-
Pre-instillation nocturia (N)	4.1±0.56	3.05±0.52	0.7540
Pre-instillation QoL	80±11.2	78±12.4	0.6211

C – Continent; IC – Incontinent; DO – Detrusor Over-activity

Table 3. Treatment characteristics


Followed parameters	Group I	Group II
Number of instillations	9.47±1.49	9.23±1.65
No. of patients having completed treatment	30	24
Duration of treatment (weeks)	23.4±5.92	21.9±8.79
Duration of follow-up from treatment (months)	19.9±5.98	15.23 ±6.88

**Table 4. Summary of data retrieved from studies on intravesical HA for UTIs and IC/PBS**

HA regime treatment; symptoms evaluated; no. of patients	Type of the study; follow-up time	Results	Reference
UTIs			
9 intravesical instillation over 6 months; UTI recurrence; n=20	Prospective 47.6 weeks compared with retrospective review of patient charts covering 36.2±6.2 weeks	<i>No. infections/year/ patient: 4.99±0.92 to 0.56±0.82 (p&lt;0.001). Time to recurrence: 178.3±25.5 days to 76.7±24.6 (p&lt;0.001).</i>	<u>Lipovac et al., 2007</u>
1/week intravesical instillation for 4 weeks, then 1/month for 4 months; UTI recurrence; n=40	Prospective follow-up of 12.4 months, compared with retrospective review of patient charts covering 15.8 months	<i>The mean (SD) rate of UTI/patient/year: 4.3 (1.55) to 0.3 (0.55) (p&lt;0.001). The median time to recurrence after HA: 498 days vs. 96 days beforehand (p&lt;0.001). Tolerability/adverse effects: 9 patients reported mild bladder irritation, no patient interrupted the treatment.</i>	Constantinides et al., 2004
Intravesical instillations 1/week for 1 month + once every others week for 2 months + 1/month for 5 months; urine cultures, UTI recurrence; n=30	Prospective study; follow-up 11 months after complete therapy	<i>53 % negative urine cultures during the months of treatment phase. Recurrence free at the end of follow-up.</i>	Sharifiaghdas and Hamzehi, 2010
9 intravesical instillations 23 weeks; Prophylactic antibiotic, VAS, day-time frequency, quality of life, urgency, nocturia, bladder volume change at 1, 3, 6 and 9 months; n=30 on prophylactic antibiotic therapy during the study period	Prospective study; follow-up 19.9±5.98 after complete therapy	<i>Prophylactic antibiotic: 60 % complete response, interrupted antibiotic treatment; 20 % continued the low-dose prophylactic treatment. Statistically significant improvements: bladder pain, day-time frequency and quality of life. Tolerability/adverse effects: 6 patients reported bladder irritation with no interruption of treatment.</i>	This study
IC/PBS			
1/week bladder instillations for 1 month + 1/month instillations for 2 months, patients were then offered further 1/month instillations; urinary frequency,	Prospective, unblinded, uncontrolled pilot study; subsequently evaluated after 3 years	<i>Mean decreases in nocturia and pain of 40 % and 30 %, respectively. Decrease in analgesic use. Tolerability/adverse effects: tolerated by all patients.</i>	Kallestrup et al. (2005)



use of analgesics and pain			
1/week instillations; VAS, quality of life; n=126	Prospective study; follow-up 5 years	<p><i>Symptoms improvement:</i> 85% reported (<math>\geq 2</math> VAS units), VAS score of 8.5 decreased to 3.5 after therapy (<math>p &lt; 0.0001</math>).</p> <p><i>Quality of life:</i> 101 patients (84 %) significant improvement.</p>	Riedl et al. (2008)
4 weekly intravesical instillations + 5 monthly instillations; Interstitial Cystitis Symptom and Problem Indexes, VAS, functional bladder capacity, frequency and nocturia in voiding diary, maximum flow rate, voided volume, postvoid residual volume, and quality of life, at 1, 3 and 6 months; n=30	Prospective, randomized study	<p><i>Statistically significant improvements:</i> Interstitial Cystitis Symptom Index, Interstitial Cystitis Problem Index and total score, VAS, functional bladder capacity, maximum flow rate, and Quality of Life Index, after 6 months in both groups.</p>	Lai et al., 2013
9 intravesical HA instillations over nearly 22 weeks; VAS, day-time frequency, quality of life, urgency, nocturia, bladder volume change at 1, 3, 6 and 9 months; n=24	Prospective study; 15 months follow-up period	<p>75 % of the patients demonstrated a complete response.</p> <p><i>Statistically significant improvements:</i> pain score, life quality, urgency and nocturia.</p>	This study



54 patients

**Group I**  
30 - UTIs

9.47 ± 1.49  
instillations

After 20 months

Intra-vesical instillations  
50 ml/40mg

9.23 ± 1.65  
instillations

After 15 months

**Group II**  
24 - BPS/IC

1. The Pelvic Pain and Urinary/Frequency Patient Symptom Scale questionnaires (PUF)
2. Visual analog scale (VAS)
3. The Quality of Life Scale (QoLS).

- Pain score (N/10)
- Day-time frequency (N)
- Quality of life
- Urgency (N/10)
- Nocturia (N/10)
- Bladder volume (mL)
- Adverse effects

HA installation is an effective GAG substitution therapy in patients with recurrent UTIs and IC/BPS that were resistant to other types of therapy